Aptamer Group PLC

LSE:APTA UK Biotechnology
Market Cap
$270.72K
GBX2.23 Billion GBX
Market Cap Rank
#46696 Global
#980 in UK
Share Price
GBX0.83
Change (1 day)
+0.00%
52-Week Range
GBX0.25 - GBX1.30
All Time High
GBX153.00
About

Aptamer Group PLC, together with its subsidiaries, provides synthetic binders for research, diagnostics, and therapeutics in the United Kingdom, rest of Europe, the United States, and internationally. The company offers Optimer, a platform that enables the discovery and development of optimized DNA and RNA aptamers, which can bind to target molecules. Its platform is used in research reagent and … Read more

Aptamer Group PLC (APTA) - Net Assets

Latest net assets as of June 2025: GBX1.38 Million GBX

Based on the latest financial reports, Aptamer Group PLC (APTA) has net assets worth GBX1.38 Million GBX as of June 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX2.83 Million) and total liabilities (GBX1.45 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets GBX1.38 Million
% of Total Assets 48.76%
Annual Growth Rate 7.11%
5-Year Change 1216.19%
10-Year Change N/A
Growth Volatility 2820.39

Aptamer Group PLC - Net Assets Trend (2019–2025)

This chart illustrates how Aptamer Group PLC's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Aptamer Group PLC (2019–2025)

The table below shows the annual net assets of Aptamer Group PLC from 2019 to 2025.

Year Net Assets Change
2025-06-30 GBX1.38 Million +55.81%
2024-06-30 GBX887.00K +191.78%
2023-06-30 GBX304.00K -96.22%
2022-06-30 GBX8.05 Million +7567.62%
2021-06-30 GBX105.00K -57.28%
2020-03-31 GBX245.81K -72.68%
2019-03-31 GBX899.87K --

Equity Component Analysis

This analysis shows how different components contribute to Aptamer Group PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 1245216100.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (June 2025)

Component Amount Percentage
Common Stock GBX1.99 Million 144.07%
Other Comprehensive Income GBX619.00K 44.79%
Other Components GBX13.63 Million 986.54%
Total Equity GBX1.38 Million 100.00%

Aptamer Group PLC Competitors by Market Cap

The table below lists competitors of Aptamer Group PLC ranked by their market capitalization.

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Aptamer Group PLC's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 887,000 to 1,382,000, a change of 495,000 (55.8%).
  • Net loss of 2,424,000 reduced equity.
  • New share issuances of 2,891,000 increased equity.
  • Other comprehensive income increased equity by 115,000.
  • Other factors decreased equity by 87,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income GBX-2.42 Million -175.4%
Share Issuances GBX2.89 Million +209.19%
Other Comprehensive Income GBX115.00K +8.32%
Other Changes GBX-87.00K -6.3%
Total Change GBX- 55.81%

Book Value vs Market Value Analysis

This analysis compares Aptamer Group PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1070.78x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has increased from 63.21x to 1070.78x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2019-03-31 GBX0.01 GBX0.83 x
2020-03-31 GBX0.00 GBX0.83 x
2021-06-30 GBX0.00 GBX0.83 x
2022-06-30 GBX0.12 GBX0.83 x
2023-06-30 GBX0.00 GBX0.83 x
2024-06-30 GBX0.00 GBX0.83 x
2025-06-30 GBX0.00 GBX0.83 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Aptamer Group PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -175.40%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -201.50%
  • • Asset Turnover: 0.42x
  • • Equity Multiplier: 2.05x
  • Recent ROE (-175.40%) is above the historical average (-742.73%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2019 -50.56% -46.11% 0.71x 1.55x GBX-544.97K
2020 -274.50% -78.96% 0.61x 5.65x GBX-699.31K
2021 -1761.52% -144.50% 0.62x 19.66x GBX-1.86 Million
2022 -26.00% -51.86% 0.35x 1.43x GBX-2.90 Million
2023 -2577.63% -447.26% 0.64x 9.06x GBX-7.87 Million
2024 -333.48% -343.95% 0.31x 3.12x GBX-3.05 Million
2025 -175.40% -201.50% 0.42x 2.05x GBX-2.56 Million

Industry Comparison

This section compares Aptamer Group PLC's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $11,113,250
  • Average return on equity (ROE) among peers: -147.03%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Aptamer Group PLC (APTA) GBX1.38 Million -50.56% 1.05x $3.12K
4BASEBIO UK SOCIETAS (4BB) $11.70 Million -27.66% 0.26x $10.53K
Arecor Therapeutics PLC (AREC) $773.79K -355.70% 4.54x $3.33K
Bioventix (BVXP) $4.20 Million 36.18% 0.07x $9.85K
Cizzle Biotechnology Holdings PLC (CIZ) $741.00K -0.02% 3.16x $747.56
Fusion Antibodies PLC (FAB) $1.46 Million 79.21% 0.28x $2.07K
Faron Pharmaceuticals Oy (FARN) $1.61 Million -823.73% 5.34x $27.00K
Futura Medical (FUM) $9.72 Million -50.98% 0.21x $424.60
hVIVO plc (HVO) $2.86 Million -195.31% 2.17x $5.18K
International Biotechnology Trust plc (IBT) $66.95 Million 14.71% 0.00x $1.10K